ABC Arbitrage SA acquired a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 26,939 shares of the company's stock, valued at approximately $451,000.
Separately, Private Advisor Group LLC acquired a new position in shares of Telix Pharmaceuticals during the 1st quarter worth $170,000.
Analysts Set New Price Targets
Several analysts recently commented on TLX shares. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. Wedbush reiterated an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, June 12th. Finally, HC Wainwright assumed coverage on Telix Pharmaceuticals in a research note on Thursday, July 3rd. They set a "buy" rating and a $23.00 price target on the stock.
View Our Latest Report on TLX
Telix Pharmaceuticals Stock Performance
Shares of Telix Pharmaceuticals stock traded down $0.44 on Friday, hitting $11.34. The company's stock had a trading volume of 155,231 shares, compared to its average volume of 64,757. Telix Pharmaceuticals Limited has a 52-week low of $11.34 and a 52-week high of $30.36. The firm has a fifty day moving average price of $15.59 and a 200-day moving average price of $16.75. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.
Telix Pharmaceuticals Profile
(
Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
